| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | bemnifosbuvir + ruzasvir (BEM/RZR) Chronic hepatitis C virus (HCV) infection — regulatory filing planning (NDA timeline expectation) | NDA | — | Small Molecules | Infectious Diseases | ||
NDA Submission example | bemnifosbuvir + ruzasvir (BEM/RZR) Chronic hepatitis C virus (HCV) infection — regulatory filing planning (NDA timeline expectation) | NDA | — | Small Molecules | Infectious Diseases | ||
NDA Submission example | bemnifosbuvir + ruzasvir (BEM/RZR) Chronic hepatitis C virus (HCV) infection — regulatory filing planning (NDA timeline expectation) | NDA | — | Small Molecules | Infectious Diseases |
Recent Updates
Recently added Catalysts
Atea Pharmaceuticals, Inc.$4.98
+0.2 (+4.18%)
C 51Pipeline Score Fair Value Pharma · Clinical
Market Cap
341.72 M
EPS
-2.12
P/E Ratio
-2.01 $
Value Trade
1.40 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
41.13 M
Operating CF
-46.39 M
Total Assets
267.08 M
Total Liabilities
267.08 M
Equity
233.71 M
D/E Ratio
12,345
4.74 %
Week
-20.22 %
1 Month
-6.55 %
3 Month
47.33 %
6 Month
-80.55 %
5 Year
-83.64 %
All Time
Cash Data
Cash Position
256.01 M
Monthly Burn
15.46 M
Runway
15.1 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
415.17 K
52 Week Range
2.78 - 6.45
% held by Insiders
20.86 %
% held by Institutions
72.34 %
Enterprise Value
86.34 M
Total Shares
78.12 M
Short %
12.97 %
Float Shares
54.52 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Atea Pharmaceuticals, Inc.
300Total events
5Upcoming
73Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 5
TBD
T2Trial Initiation
Advance AT-587 into Phase 1 for HEV after completion of first-in-human enabling studies
Event history 295
Jun 25, 2026
▲Enrollment CompleteBemnifosbuvir-RuzasvirTrial
Completed patient enrollment in Phase 3 C-FORWARD trial
hepatitis C virussource ↗
Jun 2026
◆Topline ReadoutBemnifosbuvir-RuzasvirClinical Data
Topline results from C-BEYOND expected mid-year 2026
hepatitis C virussource ↗
Jun 2026
◆Trial InitiationAT-587Trial
Anticipates initiating clinical development of AT-587 for HEV in mid-2026
hepatitis E virussource ↗
Jun 2026
Jun 2026
◆Topline ReadoutBemnifosbuvir-RuzasvirClinical Data
Topline results from Phase 3 C-BEYOND trial in North America
Hepatitis C virus (HCV)source ↗
Jun 2026
▲Enrollment CompleteBemnifosbuvir-RuzasvirTrial
Enrollment completion expected for Phase 3 C-FORWARD trial outside North America
Hepatitis C virus (HCV)source ↗
May 29, 2026
▲Poster PresentationBemnifosbuvir-RuzasvirPresentation
Poster FRI-636: BEM/RZR low potential to inhibit P-gp, BCRP, OATP1B1/3
hepatitis C virussource ↗
May 28, 2026
▲Poster PresentationAT-587Presentation
Poster TOP-631: Discovery and preclinical profile of AT-587
hepatitis E virussource ↗
May 12, 2026
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Business Update Conference Call
Q2 2026
◆Trial InitiationAT-587Trial
Initiation of Phase 1 clinical program for AT-587
Hepatitis E virus (HEV) infectionsource ↗
Q2 2026
◆Topline ReadoutBemnifosbuvir-RuzasvirClinical Data
Topline results expected mid-2026
hepatitis C virussource ↗
Q2 2026
◆Enrollment CompleteBemnifosbuvir-RuzasvirTrial
Enrollment completion expected mid-2026
hepatitis C virussource ↗
Drug Pipeline Intelligence
C51
Pipeline Score $397M
Pipeline ValueFair Value
Valuation Signal10
Drugs Scored1.2x
rNPV / MCap Top 80%
Micro Cap (rank 182 of 905)
Percentile RankAtea Pharmaceuticals, Inc. carries a moderate pipeline score (51/100), with $1.6B risk-adjusted pipeline value, led by AT-527 in Hepatitis C (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AT-527 Small molecule | Hepatitis C | Phase 2 | NCT04019717 | 21% | $651M | COMPLETED | 10 | - | - | Mar 23, 2020 | - | May 4, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
bemnifosbuvir and ruzasvir | hepatitis C virus | Phase 1 | 2026-05-27 | |||
bemnifosbuvir and ruzasvir | hepatitis C virus | Phase 1 | 2026-05-27 | |||
bemnifosbuvir and ruzasvir | hepatitis C virus | Phase 1 | 2026-05-27 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AVIR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AVIR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AVIRAtea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals has completed patient enrollment in its Phase 3 C-FORWARD trial, evaluating bemnifosbuvir and ruzasvir for hepatitis C treatment. Over 880 treatment-naïve patients were enrolled across 17 countries. The trial aims to compare the new regimen against the current standard of care, with topline results expected by year-end 2026.
Read more →AVIRAtea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Atea Pharmaceuticals presented promising Phase 1 results for its fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) at the EASL Congress 2026. The regimen demonstrated a low risk of drug-drug interactions, supporting its use alongside commonly prescribed medications. Additionally, data for AT-587, a potential treatment for hepatitis E virus, showed high antiviral potency and efficacy. These findings suggest a strong potential for BEM/RZR to become a best-in-class option for hepatitis C treatment.
Read more →AVIRAtea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its Q1 2026 financial results, highlighting progress in its Phase 3 trials for Hepatitis C Virus (HCV) and the upcoming initiation of a Phase 1 trial for Hepatitis E Virus (HEV). The company is optimistic about its HCV treatment regimen, which has shown high efficacy in earlier studies. Additionally, Atea's financial standing remains strong with significant cash reserves.
Read more →AVIRAtea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
Atea Pharmaceuticals announced that three abstracts have been accepted for presentation at the EASL Congress 2026, showcasing advancements in their viral hepatitis pipeline. The presentations will focus on their fixed-dose combination treatment for hepatitis C and preclinical data for AT-587, a candidate for hepatitis E. The company aims to address significant unmet needs in viral hepatitis treatment.
Read more →AVIRAtea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Atea Pharmaceuticals will host a conference call on May 12, 2026, to discuss its first quarter financial results and provide a business update. The call will be accessible via a live audio webcast and telephone. Atea is focused on developing oral antiviral therapies, with ongoing clinical programs for HCV and HEV.
Read more →AVIRAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from Nor
Atea Pharmaceuticals reported its fourth quarter and full-year financial results for 2025, highlighting advancements in its global Phase 3 program for hepatitis C virus (HCV) treatment. The company is anticipating topline results from two pivotal trials, C-BEYOND and C-FORWARD, in mid-2026 and late 2026, respectively. Atea also introduced a new hepatitis E virus (HEV) program, with a lead candidate, AT-587, expected to enter clinical development by mid-2026. While the company shows strong execution in advancing its HCV program, it faces financial challenges with a notable decrease in cash reserves since last year.
Read more →AVIRAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
Atea Pharmaceuticals will host a conference call on March 5, 2026, to discuss its fourth quarter and full year 2025 financial results. The call will also provide a business update regarding its antiviral therapies. Atea is focused on developing treatments for serious viral diseases and advancing its product pipeline.
Read more →AVIRAtea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Atea Pharmaceuticals announced promising preclinical results for AT-587, a potential first-in-class treatment for Hepatitis E virus (HEV). The results, presented at CROI 2026, showed AT-587's high potency and safety in vitro. The company plans to initiate a Phase 1 clinical program for AT-587 by mid-2026, addressing the urgent need for effective HEV therapies.
Read more →AVIRAtea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline
Atea Pharmaceuticals will outline its 2026 strategic priorities at the upcoming J.P. Morgan Healthcare Conference. The company plans to present topline results from its global Phase 3 C-BEYOND and C-FORWARD trials for its HCV treatment regimen, expected in mid to late 2026. Additionally, Atea will initiate its Phase 1 program for the HEV candidate, AT-587, anticipated for mid-2026. Atea emphasizes its commitment to developing effective antiviral therapies and addressing gaps in the current treatment landscape.
Read more →AVIRAtea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. CEO Jean-Pierre Sommadossi and the management team will present at the event, showcasing their advancements in oral antiviral therapeutics. The company is recognized for addressing serious viral diseases with a robust pipeline built on a proprietary nucleos(t)ide prodrug platform. A live and archived webcast of their presentation will be available through the company’s website.
Read more →AVIRAtea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals has completed patient enrollment in the C-BEYOND Phase 3 trial, involving over 880 treatment-naïve patients across the US and Canada. This trial evaluates the efficacy of a fixed-dose combination regimen of bemnifosbuvir and ruzasvir against existing treatments for hepatitis C virus. Topline results are anticipated by mid-2026, marking a significant step in Atea's efforts to enhance HCV treatment options.
Read more →AVIRAtea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its CEO Jean-Pierre Sommadossi and the management team will participate in the 8th Annual Evercore Healthcare Conference. The event is scheduled for December 3, 2025, at 10:00 a.m. ET in Coral Gables, FL. A live webcast and archived version will be available on Atea’s website. Atea is focused on developing oral antiviral therapies, leveraging its proprietary platform to address unmet medical needs in viral infections.
Read more →AVIRAtea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its third quarter 2025 financial results, highlighting progress in its global Phase 3 program for treating Hepatitis C Virus (HCV). The company announced new data supporting the efficacy of bemnifosbuvir and ruzasvir, and introduced a new development program for Hepatitis E Virus (HEV). Patient enrollment for the ongoing trials is on track, with topline results expected in mid-2026.
Read more →AVIRAtea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Atea Pharmaceuticals presented new modeling data at The Liver Meeting 2025, indicating that their fixed-dose combination of bemnifosbuvir and ruzasvir could achieve near-complete inhibition of hepatitis C virus replication. The regimen demonstrated a high sustained virologic response rate of 98% in treatment-adherent patients. The findings support the regimen's potential as a best-in-class, short-duration treatment option for hepatitis C.
Read more →AVIRAtea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
Atea Pharmaceuticals will host a conference call on November 12, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025, and provide a business update. The meeting will be available through a live audio webcast and participants can join by telephone. Atea continues to work on antiviral therapies, highlighting its commitment to addressing unmet medical needs in treating serious viral infections.
Read more →AVIRAtea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
Atea Pharmaceuticals will host a virtual KOL panel on November 13, 2025, focusing on hepatitis C virus (HCV) topics. The event will feature discussions on patient care, public policy, and Atea's Phase 3 trials for its antiviral regimen. Key opinion leaders in HCV will participate, highlighting the importance of early diagnosis and treatment.
Read more →AVIRAtea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025
Atea Pharmaceuticals announced it will present new data on the combination of bemnifosbuvir and ruzasvir at The Liver Meeting 2025. The data suggests that this regimen could be a best-in-class treatment for hepatitis C (HCV) infection, highlighting promising results from Phase 2 studies. The company is currently advancing a Phase 3 program aimed at further evaluating the effectiveness of this treatment, showcasing strong response rates in patients. A virtual investor event is also planned post-conference to discuss the ongoing development and market opportunities for HCV treatments.
Read more →AVIRAtea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Atea Pharmaceuticals will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The management team will engage in a fireside chat, which will be available via live webcast. Atea focuses on developing oral antiviral therapies, with a lead program targeting HCV in Phase 3 development.
Read more →AVIRAtea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Includ
Atea Pharmaceuticals reported financial results for Q2 2025 and provided an update on its global Phase 3 program for HCV treatment. The company’s regimen, combining bemnifosbuvir and ruzasvir, shows promising results with a 98% sustained virologic response at 12 weeks after treatment. Patient enrollment is progressing well in both C-BEYOND and C-FORWARD trials. However, HCV remains a significant health challenge globally, with millions still affected despite existing therapies.
Read more →AVIRAtea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
Atea Pharmaceuticals will host a conference call on August 7, 2025, to discuss its second quarter financial results and provide a business update. The call will be accessible via telephone and webcast, allowing investors to stay informed about the company's progress in developing antiviral therapies. Atea's lead program focuses on treating HCV with innovative drug combinations.
Read more →AVIRAtea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
Atea Pharmaceuticals has initiated the global Phase 3 C-FORWARD trial for its HCV treatment regimen, bemnifosbuvir and ruzasvir. This trial follows the C-BEYOND trial currently enrolling patients in North America. The regimen aims to offer a more convenient and effective treatment option for hepatitis C, addressing the needs of a diverse patient population.
Read more →AVIRAtea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzas
Atea Pharmaceuticals reported its first quarter 2025 financial results alongside a business update, highlighting ongoing patient enrollment in the Phase 3 C-BEYOND trial for hepatitis C virus (HCV) treatment. The company shared positive Phase 2 trial results for its drug regimen of bemnifosbuvir and ruzasvir, indicating a high sustained virologic response rate among participants. Atea plans to initiate a second Phase 3 trial, C-FORWARD, later in the year while hosting a key opinion leader event to discuss ongoing developments in HCV treatment. Atea also noted a cash reserve of $425.4 million, reflecting strong financial health as they continue their research efforts.
Read more →AVIRAtea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its Q1 2025 financial results, highlighting the ongoing enrollment in the Phase 3 C-BEYOND trial for its HCV treatment regimen of bemnifosbuvir and ruzasvir. Positive Phase 2 data showcased the treatment's efficacy and potential best-in-class profile, which may positively impact the HCV market. Additionally, Atea announced a virtual investor event for May 14, 2025, to discuss the latest updates in HCV treatment. However, the company also revealed a workforce reduction of approximately 25% as part of cost-cutting measures amidst an ongoing strategic review.
Read more →AVIRAtea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
Atea Pharmaceuticals announced promising results from its Phase 2 study of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). The study demonstrated a 98% sustained virologic response rate at 12 weeks post-treatment after a short 8-week regimen. Additionally, it showed low risk for drug-drug interactions with commonly used HIV treatments and was well tolerated by patients, including those with hepatic or renal impairment. Further insights from the results will be discussed during a virtual investor event scheduled for May 14, 2025.
Read more →AVIRAtea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
Atea Pharmaceuticals will host a virtual key opinion leader panel to address challenges faced by patients with hepatitis C virus (HCV) on May 14, 2025. The panel will discuss results from Atea's Phase 2 study featuring bemnifosbuvir and ruzasvir. This event replaces the company's first quarter earnings call and emphasizes the strategic direction regarding HCV therapies. Notable physicians from various global institutions will share their insights on current treatments and future prospects in HCV management.
Read more →AVIRAtea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
Atea Pharmaceuticals has announced the upcoming presentation of new data from its Phase 2 clinical study on bemnifosbuvir and ruzasvir for treating hepatitis C at the EASL Congress 2025. The regimen is touted for its efficacy, safety, and potential best-in-class profile, aiming to address the significant global health burden of hepatitis C. Following the successful Phase 2 results, Atea has initiated a global Phase 3 program to further evaluate this promising therapy.
Read more →AVIRAtea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program Enters into Agreement with Bradley L. Radoff and Michael Torok BOSTON
Atea Pharmaceuticals has appointed Howard H. Berman to its Board of Directors. Dr. Berman will act as a non-voting observer until the 2025 Annual Meeting when he will become a full voting member. The company also authorized a share repurchase program of up to $25 million, aiming to enhance shareholder value while pursuing strategic alternatives, including partnerships and acquisitions related to their HCV treatment development. This initiative comes as Atea advances its Phase 3 trials for bemnifosbuvir and ruzasvir.
Read more →AVIRAtea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals has initiated the dosing of the first patient in its C-BEYOND Phase 3 trial, evaluating a regimen of bemnifosbuvir and ruzasvir for chronic hepatitis C virus (HCV) treatment. The trial, conducted in the U.S. and Canada, seeks to determine the effectiveness of this combination therapy against current standard treatments. Atea's approach aims to address the significant global health burden posed by HCV, which affects approximately 50 million people worldwide. The company has reported positive outcomes from preliminary studies, contributing to the anticipation surrounding this innovative treatment.
Read more →AVIRAtea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
Atea Pharmaceuticals has taken several decisive actions to enhance shareholder value, including reducing its workforce by 25% and launching a strategic review with external assistance. The company has engaged an independent financial advisor to identify potential opportunities, particularly for its Phase 3 program targeting hepatitis C. Additionally, Atea appointed Arthur S. Kirsch to its board, adding expertise to its governance. These steps reflect Atea's commitment to engaging with shareholders and optimizing its operational strategy.
Read more →AVIRAtea Pharmaceuticals Issues Statement Regarding Director Nominations No Shareholder Action is Required at this Time BOSTON
Atea Pharmaceuticals has announced that it has received a notice from Bradley L. Radoff concerning his intention to nominate three director candidates for election at the 2025 Annual Meeting of Stockholders. The company emphasizes that no action is required from shareholders at this moment, and the Board of Directors will assess the nominations in due course. Atea also reiterated its commitment to maintaining regular communication with its shareholders as it evaluates strategies to enhance value.
Read more →AVIRAtea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
Atea Pharmaceuticals announced the presentation of preclinical data on bemnifosbuvir at the 38th International Conference on Antiviral Research in 2025. The data supports the drug's potential as an oral treatment for hepatitis C virus (HCV) when combined with ruzasvir. Atea expects to begin patient enrollment for its global Phase 3 program in April 2025, following favorable results from its Phase 2 study. The company's innovative approach to HCV treatment seeks to address an urgent need in the market.
Read more →AVIRAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus ( HCV) Patie
Atea Pharmaceuticals reported its financial results for Q4 and the full year 2024, announcing a successful End-of-Phase 2 meeting with the FDA. The company is set to initiate patient enrollment for its global Phase 3 program targeting Hepatitis C in April 2025, following positive Phase 2 trial results. Despite the promising clinical developments, Atea is facing financial difficulties, including a workforce reduction to cut costs and increased operating losses over the year. The company aims to enhance shareholder value through strategic partnerships and efficient resource management.
Read more →AVIRAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
Atea Pharmaceuticals, Inc. has announced a conference call scheduled for March 6, 2025, to discuss financial results for the fourth quarter and full year of 2024. The call will include a business update regarding their ongoing development of oral antiviral therapeutics. Atea is committed to addressing unmet medical needs in serious viral infections, particularly through its product candidates aimed at treating HCV. Access to the call will be available via audio webcast and telephone registration.
Read more →AVIRAtea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
Atea Pharmaceuticals has appointed Arthur S. Kirsch to its Board of Directors, effective immediately. Kirsch has over 30 years of experience in investment banking and extensive knowledge of the healthcare and life sciences sectors. His role is expected to bolster Atea's strategic initiatives, particularly in exploring partnerships for its Phase 3 program involving the treatment of hepatitis C. Atea aims to enhance its shareholder value under his guidance and expertise.
Read more →AVIRAtea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference Global Phase 3 HCV Program Expected to Initiate in 1Q 2025 Potential Best-in-Class Profile of Bemnifosbuvir
Atea Pharmaceuticals announced its strategic priorities for 2025 at the J.P. Morgan Healthcare Conference, focusing on the initiation of a global Phase 3 program for its HCV treatment regimen, bemnifosbuvir and ruzasvir, expected in 1Q 2025. The regimen is positioned to leverage a significant market opportunity, with potential best-in-class attributes expected to improve patient outcomes in HCV therapy. Recent market studies indicate favorable opinions from healthcare providers and payors regarding the new treatment. The company boasts a strong cash position, likely ensuring continued development efforts through 2028.
Read more →AVIRAtea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, Inc. announced that its CEO, Jean-Pierre Sommadossi, will present a business update at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, in San Francisco. The presentation will cover Atea's focus on developing oral antiviral therapeutics for serious viral diseases. A live webcast and an archived version will be available on the company’s website following the event. Atea continues to enhance its pipeline, currently leading with a combination therapy targeting HCV.
Read more →AVIRAtea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
Atea Pharmaceuticals has engaged Evercore, an independent investment bank, to explore strategic partnerships aimed at enhancing shareholder value, particularly regarding its advanced program for hepatitis C. While no timetable has been set for concluding the review or making decisions, the announcement signals proactive steps in the company's strategy. There is also no guarantee that this process will lead to a specific outcome or transaction, reflecting inherent uncertainties in their plans.
Read more →AVIRAtea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
Atea Pharmaceuticals announced the successful results of its Phase 2 study on a combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). The study achieved a remarkable 98% sustained virologic response (SVR12) after just eight weeks of treatment among adherent patients. The treatment showed a favorable safety profile, with no serious adverse events reported. The company plans to move forward with a Phase 3 program in early 2025, indicating strong potential for addressing unmet needs in the HCV market.
Read more →AVIRAtea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced that its CEO, Jean-Pierre Sommadossi, along with the management team, will present a business update at the upcoming Evercore HealthCONx Conference on December 4, 2024. The presentation aims to cover key developments in the company's efforts to discover and commercialize oral antiviral therapeutics for serious viral infections. A live webcast will be available, and an archived version will be accessible for at least 90 days post-event.
Read more →AVIRAtea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Atea Pharmaceuticals presented significant data at The Liver Meeting 2024 supporting the use of bemnifosbuvir and ruzasvir in treating hepatitis C virus (HCV). The ongoing Phase 2 trial shows promising results, including a 97% sustained virologic response rate at 12 weeks post-treatment. The combination aims to address treatment challenges, with plans for further development anticipated from Atea in the coming months. A detailed study provided insights into the combination's efficacy and resistance profile.
Read more →AVIRAtea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4 24 New Data Supportive of HCV Com
Atea Pharmaceuticals has reported its third quarter 2024 financial results while providing an update on its Hepatitis C Virus (HCV) drug development program. The company anticipates topline SVR12 results from a Phase 2 study comparing bemnifosbuvir and ruzasvir in December 2024, supporting its ongoing advancements toward a global Phase 3 trial. Additionally, they presented successful preliminary data indicating high efficacy rates in patients prior to the anticipated results. However, the company faced challenges with its COVID-19 trial not meeting primary endpoints, impacting strategic directions.
Read more →AVIRAtea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
Atea Pharmaceuticals announced that they will host a live conference call on November 7, 2024, to report their financial results for the third quarter ending September 30, 2024. The call will also provide a business update, emphasizing the company's ongoing focus on developing oral antiviral therapeutics. Participants can join via telephone or through an audio webcast available on the company's website. Atea aims to expand its antiviral pipeline, highlighting their lead program targeting hepatitis C virus.
Read more →AVIRAtea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Atea Pharmaceuticals is set to present new data supporting the combination treatment of bemnifosbuvir and ruzasvir for Hepatitis C Virus at the AASLD's The Liver Meeting 2024. This combination, currently in Phase 2 development, aims to address the significant unmet medical needs of HCV patients, particularly those with comorbidities. The presentations will include various studies on efficacy and safety, indicating a strong potential for this combination therapy to improve treatment outcomes. The company is optimistic about progressing to Phase 3 development following the meeting.
Read more →AVIRAtea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
Atea Pharmaceuticals announced the results of its Phase 3 SUNRISE-3 trial for bemnifosbuvir, intended for treating COVID-19. The trial found no significant reduction in hospitalization or death amongst high-risk patients. Despite bemnifosbuvir being generally safe and well tolerated, Atea will not seek regulatory approval for the drug due to the disappointing results. The company plans to continue its focus on bemnifosbuvir's development for hepatitis C in combination with ruzasvir, with further data expected later in 2024.
Read more →AVIRAtea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
Atea Pharmaceuticals has announced the publication of additional data regarding bemnifosbuvir's metabolic activation pathway in the journal PLOS Biology. The article highlights how bemnifosbuvir is converted into its active metabolite, AT-9010, showing selective inhibition of viral enzymes that could lead to effective treatments for COVID-19 and hepatitis C virus (HCV). The data also indicates bemnifosbuvir's potential efficacy against various SARS-CoV-2 variants and its favorable safety profile. The drug has received Fast Track designation from the FDA, emphasizing its promise as an antiviral therapy.
Read more →AVIRAtea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q 24 Bemnifosbuvi
Atea Pharmaceuticals reported strong progress in its clinical trials during Q2 2024, achieving full enrollment in its global Phase 2 study for hepatitis C virus (HCV) treatments and its Phase 3 SUNRISE-3 trial for COVID-19. The results of this HCV trial are expected in Q4 2024, with the company presenting promising early data at the EASL Congress showing high rates of sustained virologic response. Additionally, the company has maintained robust financial resources, with approximately $502.2 million available. The focus remains on addressing critical unmet needs in antiviral therapies.
Read more →AVIRAtea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
Atea Pharmaceuticals will hold a live conference call on August 7, 2024, to discuss its financial results for the second quarter of 2024 and provide a business update. The event will be accessible via telephone and online through Atea's Investor Relations website. Atea is dedicated to developing oral antiviral therapies, particularly targeting serious viral infections like COVID-19 and hepatitis C. The company aims to expand its pipeline using its proprietary nucleos(t)ide prodrug platform.
Read more →AVIRAtea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
Atea Pharmaceuticals reported promising results from the lead-in cohort of their Phase 2 study for the treatment of hepatitis C virus using a combination of bemnifosbuvir and ruzasvir. The study, involving 60 participants, demonstrated a 97% sustained virologic response rate at 12 weeks post-treatment with an 8-week treatment duration. Additionally, the combination showed favorable safety and tolerability, with a 100% response rate in the difficult-to-treat genotype 3 group. These findings were presented at the EASL Congress 2024, indicating the potential for a best-in-class treatment profile.
Read more →AVIRAtea Pharmaceuticals to Present at the Jefferies Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, will present a business update at the Jefferies Healthcare Conference on June 5, 2024. The presentation will be led by CEO Jean-Pierre Sommadossi and will include a live webcast accessible via the company's website. Atea is dedicated to developing oral antiviral therapeutics for serious viral infections, particularly focusing on COVID-19 and hepatitis C. This presentation reflects Atea's commitment to advancing its pipeline of antiviral treatments.
Read more →AVIRAtea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
Atea Pharmaceuticals is set to present new data on the combination of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV) at the EASL Congress 2024. The Phase 2 study results aim to demonstrate the antiviral efficacy of this best-in-class treatment approach, particularly in the context of rising drug resistance among HCV variants. Notably, the combination is designed to address the treatment needs of current HCV-infected patients, particularly concerning the high prevalence of resistant mutations. The company anticipates full datasets to be available after the embargo lift on June 5, 2024.
Read more →AVIRAtea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H 24 Global Phase
Atea Pharmaceuticals has reported its financial results for Q1 2024, highlighting significant operational achievements including full enrollment in the Phase 3 SUNRISE-3 trial for COVID-19. Results from this trial are expected in the second half of 2024. Additionally, the company is advancing its Phase 2 study for HCV, with promising preliminary results indicating a high sustained virologic response. However, rising costs associated with research and development are noted as a concern amidst ongoing COVID-19 challenges.
Read more →AVIRAtea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
Atea Pharmaceuticals will host a live conference call on May 14, 2024, at 4:30 p.m. ET to discuss its financial results for Q1 2024 and provide a business update. The event will allow investors to hear the latest developments in the company's antiviral therapy pipelines. Participants can access the call via telephone or audio webcast, and an archived version will be available afterward.
Read more →AVIRAtea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
Atea Pharmaceuticals has announced the presentation of Phase 1 data for bemnifosbuvir at the ESCMID Global 2024 conference. This data underscores the drug's favorable safety profile, specifically noting the absence of cardiotoxicity in healthy participants. Atea is also advancing bemnifosbuvir into a Phase 3 trial for COVID-19, and results from its ongoing Phase 2 trial for hepatitis C are expected soon. The company's commitment to addressing unmet medical needs in viral treatments remains a focal point.
Read more →AVIRAtea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Atea Pharmaceuticals has completed patient enrollment for its global Phase 3 SUNRISE-3 trial, which evaluates bemnifosbuvir for COVID-19 treatment in high-risk patients. The trial involved over 2,200 patients randomized to receive bemnifosbuvir or placebo, with results expected in the second half of 2024. The primary endpoint focuses on all-cause hospitalization or death in the supportive care cohort. Bemnifosbuvir has been granted Fast Track designation by the FDA, reflecting its potential to meet critical treatment needs.
Read more →AVIRAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohor
Atea Pharmaceuticals reported strong financial results for Q4 and full year 2023, highlighting a 98% sustained virologic response rate in their Phase 2 HCV study. The company has successfully enrolled over 1,400 patients in the Phase 3 SUNRISE-3 study for COVID-19, expecting key interim analysis results in 1H 2024. Atea aims to address significant unmet needs in HCV treatment with their drug combination and is committed to advancing antiviral options for COVID-19.
Read more →AVIRAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
Atea Pharmaceuticals has announced a live conference call scheduled for February 28, 2024, to discuss its financial results for Q4 and the full year of 2023. The call will also include a business update. Atea is focused on the development of oral antiviral therapeutics for serious viral infections, including those caused by SARS-CoV-2 and HCV. The event aims to provide insights into the company's ongoing projects and financial performance.
Read more →AVIRAtea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
Atea Pharmaceuticals reported promising results from its Phase 2 study of bemnifosbuvir and ruzasvir in treating Hepatitis C, with a 98% Sustained Virologic Response at Week 4 from 52 patients. The company has also enrolled over 650 patients in its Phase 3 SUNRISE-3 trial for COVID-19, enabling the first interim analysis by an independent board expected in March 2024. These developments highlight the company's advancements in antiviral treatments as well as its efforts to meet unmet medical needs in viral diseases. The favorable results indicate progress toward significant milestones in both clinical programs.
Read more →AVIRAtea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, Inc. has announced that its CEO, Jean-Pierre Sommadossi, will present a business update at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will highlight the company's developments in oral antiviral therapies, particularly for serious viral infections such as SARS-CoV-2 and hepatitis C. A live webcast of the event will be available, with an archived version accessible for 90 days. Atea is focused on addressing unmet medical needs in antiviral treatment through its development of novel product candidates.
Read more →AVIRAtea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
Atea Pharmaceuticals has presented promising data on the combination of bemnifosbuvir and ruzasvir for treating Hepatitis C Virus (HCV) at the AASLD The Liver Meeting 2023. Phase 1 studies indicated that the drug combination was well tolerated and demonstrated low risk of drug-drug interactions. Both drugs have shown potent antiviral activity against HCV resistant variants. Atea's CEO expressed optimism for the ongoing Phase 2 study's results, which are anticipated early in 2024.
Read more →AVIRAtea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Atea Pharmaceuticals announced that its management team will present at two upcoming investor conferences this November. The presentations will take place at the Jefferies London Healthcare Conference on November 15 and the Evercore ISI HealthCONx Conference on November 29. These events serve as platforms for Atea to provide updates on its development of oral antiviral therapeutics aimed at serious viral infections, including COVID-19 and hepatitis C. Investors can access live webcasts of the presentations through the company's website.
Read more →AVIRAtea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update Patient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis
Atea Pharmaceuticals has reported its financial results for the third quarter of 2023 and provided updates on its clinical trials. Patient enrollment is progressing in the Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19, with interim analysis expected in early 2024. The company is also advancing its Phase 2 combination trial for hepatitis C, with promising initial results anticipated early next year. Financially, Atea reported a significant increase in research and development expenses but maintains a strong cash position.
Read more →AVIRAtea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
Atea Pharmaceuticals recently announced upcoming poster presentations for bemnifosbuvir and ruzasvir at The Liver Meeting 2023. The data suggests these compounds may be effective as a combination therapy for hepatitis C virus (HCV), showcasing strong antiviral activity and safety profiles. The company is conducting a Phase 2 study that targets treatment-naïve HCV-infected patients, aiming to address a significant, underserved patient population. The presentations will occur on November 10, 2023, during the conference in Boston, MA.
Read more →AVIRAtea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced it will host a conference call on November 8, 2023, to report its financial results for Q3 2023 and provide a business update. The call will be available via live audio webcast and telephone, with a recommendation for participants to join early. Atea is focusing on the development of oral antiviral therapies for serious viral infections, including COVID-19 and hepatitis C. The company emphasizes its commitment to addressing unmet medical needs in this area.
Read more →AVIRAtea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its management team will present at the Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023. The presentation will include a business update and will be available via a live webcast, with an archived version accessible for 90 days afterward. Atea specializes in the development of oral antiviral therapies targeting serious viral infections, including COVID-19 and hepatitis C virus. The company aims to expand its product pipeline through a proprietary nucleos(t)ide prodrug platform.
Read more →AVIRAtea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 Phase 3 SUNRISE-3
Atea Pharmaceuticals has reported its financial results for Q2 2023 and provided an update on its ongoing clinical trials. The company is progressing with the Phase 3 SUNRISE-3 trial for its COVID-19 treatment, bemnifosbuvir, expanding eligibility criteria to include a wider range of high-risk patients. Atea also initiated a Phase 2 study involving bemnifosbuvir and ruzasvir for Hepatitis C, with initial results expected by the end of 2023. Overall, the company remains on track for significant clinical milestones within the next year.
Read more →AVIRAtea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
Atea Pharmaceuticals will host a live conference call on August 8, 2023, to discuss its financial results for the second quarter of 2023, which ended on June 30. The call will also include a business update, emphasizing the company's advancements in developing oral antiviral therapeutics for serious viral diseases. Participants can access the call through registration and a subsequent audio webcast will be available on the company's website.
Read more →AVIRAtea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
Atea Pharmaceuticals has announced the dosing of the first patient in a Phase 2 study evaluating a combination of bemnifosbuvir and ruzasvir for treating Hepatitis C Virus (HCV). This study aims to enroll approximately 280 patients and evaluate the safety and efficacy of the treatment over eight weeks. The combination therapy is expected to address the needs of a large underserved patient population affected by HCV, which continues to increase due to various factors, including the opioid crisis. Preliminary data from the trial's lead-in cohort is expected by the fourth quarter of 2023.
Read more →AVIRAtea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
Atea Pharmaceuticals' Board of Directors has unanimously rejected an unsolicited acquisition proposal from Tang Capital Partners on behalf of Concentra Biosciences. The proposal offered $5.75 per share and a contingent value right, but the Board concluded that it fundamentally undervalues Atea and is not in the best interests of the company or its shareholders. Atea is engaged in developing oral antiviral therapeutics targeting serious viral diseases like COVID-19 and hepatitis C.
Read more →AVIRAtea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
Atea Pharmaceuticals, Inc. has confirmed receiving an unsolicited acquisition proposal from Tang Capital Partners' affiliate, Concentra Biosciences, offering $5.75 per share in cash along with a contingent value right. The Board will evaluate this proposal while advising shareholders to refrain from any immediate action. This development highlights the company's potential interest in generating value for its shareholders, amidst ongoing evaluation of business opportunities.
Read more →AVIRAtea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment;
Atea Pharmaceuticals has reported its financial results for Q1 2023, highlighting significant progress in clinical trials, particularly for bemnifosbuvir in treating COVID-19 and HCV. The company is currently enrolling patients in its Phase 3 SUNRISE-3 trial for COVID-19 and anticipates initial results from its Phase 2 study combining bemnifosbuvir with ruzasvir for HCV by year-end. Atea has also presented promising data showcasing bemnifosbuvir's efficacy and safety profile at various scientific meetings, reinforcing its potential as a new standard of care for these diseases.
Read more →AVIRAtea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, will host a conference call on May 8, 2023, to report its first quarter financial results and provide a business update. The event will be accessible via live audio webcast and telephone registration. The company focuses on developing oral antiviral therapeutics for serious viral infections, including COVID-19 and hepatitis C. Atea aims to enhance its product pipeline through internal discovery and in-licensing strategies.
Read more →AVIRAtea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
Atea Pharmaceuticals has announced that the FDA has granted Fast Track designation to bemnifosbuvir, an investigational oral antiviral for COVID-19. The drug is being evaluated in the Phase 3 SUNRISE-3 trial, targeting high-risk outpatient populations. This designation could help expedite its development, addressing a significant unmet medical need in the treatment of COVID-19. The trial aims to enroll over 1,500 patients and is expected to have a global presence across multiple clinical sites.
Read more →AVIRAtea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
Atea Pharmaceuticals announced the presentation of results from the MORNINGSKY Phase 3 trial evaluating bemnifosbuvir for COVID-19 treatment at the 2023 ECCMID. The data indicated a 71% relative reduction in hospitalization rates among patients, regardless of vaccination status. Despite not meeting its primary endpoint, bemnifosbuvir demonstrated a favorable safety profile with no serious adverse events reported. The findings underscore the drug's potential to meet significant medical needs in treating COVID-19.
Read more →AVIRAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enr
Atea Pharmaceuticals has reported its financial results for 2022 and provided an update on various clinical programs. The Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19 treatment continues to enroll high-risk patients, with an interim analysis expected in the second half of 2023. In addition, Atea plans to start a Phase 2 combination study for hepatitis C treatment. However, the company has decided to deprioritize its dengue program due to the need for better diagnostics and the high costs associated with extensive trials.
Read more →AVIRAtea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
Atea Pharmaceuticals announced positive results from Phase 1 studies presented at CROI 2023, demonstrating that bemnifosbuvir has a favorable drug interaction profile. The results indicate that no dosage adjustments are necessary for drugs that are substrates of CYP3A4 or other common transporters when co-administered with bemnifosbuvir. This profile is particularly beneficial for COVID-19 patients who are at high risk for drug interactions due to multiple prescribed medications. Bemnifosbuvir is currently being evaluated in the SUNRISE-3 Phase 3 trial for non-hospitalized COVID-19 patients.
Read more →AVIRAtea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
Atea Pharmaceuticals, Inc. will host a live conference call on February 28, 2023, to discuss its financial results for the fourth quarter and full year of 2022. The event aims to provide a business update following the fiscal year. Atea, which specializes in antiviral drug development, is working on therapies for emerging viral threats, including COVID-19. The report may provide insights into the company's financial health and future direction.
Read more →AVIRAtea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
Atea Pharmaceuticals is set to present two key poster presentations related to bemnifosbuvir at the upcoming Conference on Retroviruses and Opportunistic Infections in Seattle. The findings highlight that co-administration of bemnifosbuvir does not require dose adjustments for CYP3A4 substrates and indicates a low potential for inhibiting important transport mechanisms. This data supports the drug's profile as a viable treatment option for severe viral infections, including COVID-19.
Read more →AVIRAtea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
Atea Pharmaceuticals, Inc. will present a business update at the SVB Securities Global Biopharma Conference on February 14, 2023. CEO Jean-Pierre Sommadossi and other management members will participate in a fireside chat during this event. The company focuses on developing oral therapies for severe viral diseases, leveraging its proprietary nucleos(t)ide prodrug platform. A live and archived webcast of the presentation will be accessible through the company's website.
Read more →AVIRAtea Pharmaceuticals Highlights Strategic Priorities for 2023
Atea Pharmaceuticals has outlined its strategic priorities for 2023, highlighting significant clinical milestones across its development programs for COVID-19, dengue, and Hepatitis C. The company is progressing with the SUNRISE-3 trial for bemnifosbuvir in high-risk COVID-19 patients, along with upcoming trials for AT-752 in dengue and a Phase 2 combination study of bemnifosbuvir and ruzasvir for Hepatitis C. Atea also emphasizes the strength of its financial position, enabling continued operations until 2025.
Read more →AVIRAtea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, Inc. will present a business update at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. CEO Jean-Pierre Sommadossi will discuss the company's focus on oral therapies for severe viral diseases, including COVID-19, dengue, and hepatitis C. Atea continues to develop its proprietary nucleos(t)ide prodrug platform and enhance its antiviral pipeline with new combination therapies. A live webcast of the presentation will be available, providing investors and stakeholders with insights into Atea's ongoing developments and future plans.
Read more →AVIRAtea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status Phase 3 Evaluation of Bemnifosbuvir Supported by Clinical Data from Late-Stage MORNINGSKY Trial and Prior S
Read more →AVIRAtea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members of
Read more →AVIRAtea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will participate in and present
Read more →AVIRAtea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Enrollment of SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVI
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Enrollment of SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 Expected Before Year-End 2022 Completion of Patient E
Read more →AVIRAtea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
Safety and pharmacokinetic data in healthy volunteers support ongoing clinical development AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development with a Fast Track designation from the U.S. Food and Drug Administration for treatment of dengue Den
Read more →AVIRAtea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report financial re
Read more →AVIRAtea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue
Dengue is the most prevalent mosquito-borne viral disease; endemic to 100 countries worldwide, with more than half the world’s populations at-risk AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development for treatment of dengue, showing potent in vi
Read more →AVIRAtea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19
Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19 Trial to Focus on High-Risk Patients at Greatest Risk for Disease Progression Trial Expected to Initiate in Fourth Quarter 2022 Conference Call at 8:30 a.m. ET To
Read more →AVIRAtea Pharmaceuticals Announces Upcoming Investor Events
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Atea management will participate in the following investor events in September. Bemnifosbuvir Global Phase 3 Registrati
Read more →AVIRAtea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FD
Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Emergency Task Forc
Read more →AVIRAtea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022
BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report financial resu
Read more →AVIRAtea Pharmaceuticals Participates in the William Blair Biotech Focus Conference
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals together with other members of t
Read more →AVIRAtea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a corporate overvi
Read more →AVIRAtea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient popul
Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) ver
Read more →AVIRAtea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to report financial result
Read more →AVIRAtea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting
BOSTON, March 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented two posters highlighting nonclinical data demonstrating the nonclinical safety of bemnifosbuvir (AT-527) at the Society of To
Read more →AVIRAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing to Phase 2 combination clinical trial in 2H 2022
Read more →AVIRAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report financial re
Read more →AVIRAtea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.
Read more →AVIRAtea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference
BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced that Jean-Pierre Sommado
Read more →AVIRAtea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications
BOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that new data highlighting bemnifosbuvir (AT-527) were published in the peer-reviewed journal, Nature Communications, in an ar
Read more →AVIRForward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor a
June 2020 JP Morgan Healthcare Conference January 10, 2022 Exhibit 99.1 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither histori
Read more →AVIRAtea Pharmaceuticals Highlights Strategic Priorities for 2022
COVID-19: Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials HCV: Obtained from Merck an exclusive worldwide license to ruzasvir (RZR), a Phase 2-ready, oral, potent NS5A inhibitor for development in combination
Read more →AVIRAtea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present at the 40th Annual
Read more →AVIRAtea Pharmaceuticals Added to the Nasdaq Biotechnology Index
BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December
Read more →AVIRAtea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19
Responding to the rapidly evolving SARS-CoV-2, emerging variants and changing treatment landscape, Atea is updating the development strategy for AT-527 In addition to monotherapy evaluation, expanding development program to maximize AT-527’s profile for potential use in combinat
Read more →AVIRAtea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at
Read more →AVIRAtea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche w
Read more →AVIRAtea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Virus Data
Read more →AVIRAtea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, November 11, 2021 at 4:30 p.m. ET to report financial
Read more →AVIRAtea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
Topline Phase 2 MOONSONG trial results did not meet the primary endpoint in the overall population of patients with mild or moderate COVID-19, who were mostly low-risk with mild symptoms In high-risk patients with underlying health conditions, a reduction of viral load of approx
Read more →AVIRAtea Pharmaceuticals to Present Virology and Early Clinical Data at the ISIRV-WHO Virtual Conference 2021
BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will present analyses confirming data previously reported relating to the AT-527 COVID-19 clinical trial program at th
Read more →AVIRAtea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference
BOSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea managem
Read more →AVIRAtea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea managem
Read more →AVIRAtea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses
In vitro and in vivo data demonstrate favorable safety and potency against multiple dengue virus serotypes supporting ongoing clinical development of AT-752 Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 400 million infections each year globally
Read more →AVIRAtea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results New Data in Healthy Volunteers Confirmed that AT-527 s Active Metabolite Achieved Target Antiviral Levels in L
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial BOSTON, Mass., August 12, 2021 Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ( Atea ), a clinical-stage biopharmaceutical company, today reported financial results for the second q
Read more →AVIRAtea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. ET to report financial re
Read more →AVIRAtea Pharmaceuticals to Present at William Blair Biotech Focus Conference
BOSTON, July 12, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D.,
Read more →AVIRAtea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis
Phase 2 Interim Virology Results Indicate Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting AT-527 is Being Studied in Multiple Clinical Studies, Including Global Phase 2 MOONSONG and Phase 3 MORNINGSKY Trials, with R
Read more →AVIRAtea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche
BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that it has achieved a milestone ass
Read more →AVIRAtea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs
BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior V
Read more →AVIRAtea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., F
Read more →AVIRAtea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors
BOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Di
Read more →AVIRAtea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update Global Phase 3 MORNINGSKY trial of AT-527 in the outpatient setting recently initiated for the treatment of COVID-19 Enrollm
Atea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update BOSTON, Mass., May 13, 2021 Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ( Atea ), a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended Mar
Read more →AVIRAtea Pharmaceuticals to Host First Quarter Financial Results Conference Call on May 13, 2021
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 13, 2021 at 4:30 p.m. ET to report financial result
Read more →AVIRAtea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 3 MORNINGSKY trial, a global multicenter trial evaluating AT-527 in mild o
Read more →AVIRAtea Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
– Rapid advancement of AT-527 for COVID-19 – – Strategic collaboration with Roche to develop and commercialize AT-527 for COVID-19 – – Initiation of Phase 1a trial of AT-752 for dengue fever – – Crossover financing and IPO – BOSTON, March 30, 2021 (GLOBE NEWSWIRE) -- Atea Pha
Read more →AVIRAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021
BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, March 30, 2021 at 4:30 p.m. ET to report financial res
Read more →AVIRAtea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections
High Lung Levels of Active Triphosphate Predicted with Oral AT-527 for COVID-19 Patients Data Supportive of AT-527 550 mg BID Dosing Regimen BOSTON, March 06, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company
Read more →AVIRAtea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has in-licensed the rights for AT-527 for the treatment of COVID-19 in Japa
Read more →AVIRAtea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2
BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the highly potent in vitro antiviral activity of AT-527 against SARS-CoV-2. AT-527 is
Read more →AVIRAtea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 virology trial evaluating AT-527 in mild or moderate COVID-19 patients in
Read more →AVIRAtea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications
Senior executives bring proven industry experience to leadership roles in regulatory affairs and communications BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it has e
Read more →AVIRAtea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening
Read more →AVIRAtea Pharmaceuticals Added to Russell 2000 Index
BOSTON, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it has been added to the Russell 2000® Index, effective December 21, 2020, as part of the index's quarterly initial publi
Read more →AVIRAtea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening
Read more →AVIRAtea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan
BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening
Read more →AVIRAtea Pharmaceuticals Announces Closing of Initial Public Offering
BOSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening
Read more →AVIRAtea Pharmaceuticals Announces Pricing of Initial Public Offering
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening
Read more →AVIRAtea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19
BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today
Read more →AVIRAtea Pharmaceuticals Appoints Polly Murphy, D.V.M, Ph.D., to the Board of Directors
BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Polly Murphy, D.V.M., Ph.D., Chief Business
Read more →AVIRAtea Pharmaceuticals Strengthens Management Team with Appointment of Clinical and Regulatory Leadership
BOSTON, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced the appointments of Arantxa Horga, M.D., as Executive Vice
Read more →AVIRAtea Pharmaceuticals Appoints Janet Hammond, M.D., Ph.D., as Chief Development Officer
BOSTON, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced the appointment of Janet Hammond, M.D., Ph.D., Sc.M., F.C.
Read more →AVIRAtea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing
Proceeds to support the clinical development of Atea’s oral, direct acting antiviral medicine for COVID-19, in addition to advancing its diverse pipeline of treatments for viral diseases Investigational new drug application cleared by U.S. Food and Drug Administration to start P
Read more →AVIRAtea Pharmaceuticals to Present Positive Clinical Data with At-527 for the Treatment of Chronic Hepatitis C in Patients with Cirrhosis at The Liver Meeting 2018
AT-527 is a novel pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor AT-527 shows profound and equivalent pan-genotypic antiviral activity in cirrhotic and non-cirrhotic (NC) hepatitis C virus (HCV) infected patients AT-527 was safe and well tolerated with once-d
Read more →AVIRAtea Pharmaceuticals Reports Positive Proof of Concept Clinical Data With AT-527 for the Treatment of Chronic Hepatitis C
AT-527 is a novel pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor which has been safe and well tolerated in this ongoing multiple part trial AT-527 exhibits potent antiviral activity in genotype (GT)-1b and GT-3 hepatitis C virus (HCV) infected patients with on
Read more →Competitive Position
How AVIR ranks across every disease it competes inCompetitive Position is a premium feature
See how AVIR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial